
Sanofi and GSK to Launch Phase 3 Vaccine Trial
After seeing encouraging results with their adjuvanted recombinant Covid-19 vaccine candidate across all adult age groups in a recently completed Phase 2 trial, Sanofi and GlaxoSmithKline (GSK) are preparing to launch a global Phase 3 randomized double-blind study “in the coming weeks.”








































